IMFINZI® (durvalumab) granted Priority Review in the US for …
Dec 6, 2024 · Custom Report. La Merie Publishing offers the service of preparing customized reports tailored to the needs and specifications of the customer. We conduct scientific & medical literature evaluations for clients of the biopharmaceutical industry within the scope of …
Merck Provides Update on KeyVibe and KEYFORM Clinical …
Dec 17, 2024 · RAHWAY, NJ. USA I December 16, 2024 I Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced the discontinuation of the clinical development programs for vibostolimab, an anti-TIGIT antibody, and favezelimab, an anti-LAG-3 antibody.Vibostolimab is being evaluated as an investigational fixed-dose combination with pembrolizumab (KEYTRUDA ®) in the KeyVibe program.
REGENXBIO Presents Positive Data from the Phase II Study of …
Oct 21, 2024 · Custom Report. La Merie Publishing offers the service of preparing customized reports tailored to the needs and specifications of the customer. We conduct scientific & medical literature evaluations for clients of the biopharmaceutical industry within the scope of …
Merck Announces FDA Acceptance of Biologics License …
Dec 17, 2024 · Custom Report. La Merie Publishing offers the service of preparing customized reports tailored to the needs and specifications of the customer. We conduct scientific & medical literature evaluations for clients of the biopharmaceutical industry within the scope of …
All news - Pipelinereview
2 days ago · PALO ALTO, CA and NEEDHAM, MA, USA and MELBOURNE, Australia I January 08, 2025 I Bitterroot Bio, a leader in developing innovative medicines in the field of cardio-immunology, today announced positive results from a recently completed Phase 1 study of BRB-002 in healthy volunteers. BRB-002 is a first-in-class, immune modulating protein therapy that targets CD47 […]
Neurocrine Biosciences Announces FDA Approval of CRENESSITY ...
Dec 14, 2024 · Custom Report. La Merie Publishing offers the service of preparing customized reports tailored to the needs and specifications of the customer. We conduct scientific & medical literature evaluations for clients of the biopharmaceutical industry within the scope of …
Recursion announces first patient dosed in Phase 1/2 clinical study …
Dec 3, 2024 · Custom Report. La Merie Publishing offers the service of preparing customized reports tailored to the needs and specifications of the customer. We conduct scientific & medical literature evaluations for clients of the biopharmaceutical industry within the scope of …
Kallyope Announces License Agreement with Novo Nordisk
Sep 10, 2024 · Novo Nordisk exercises option to license Kallyope-identified ligand for therapeutic development including potential treatment for obesity. NEW YORK, NY, USA I September 10, 2024 I Kallyope, a clinical stage biotechnology company discovering and developing novel therapies for diseases with high unmet need, today announced that under the terms of its research collaboration with Novo Nordisk to ...
Duality Biologics and GSK Enter Exclusive Option Agreement for a …
Dec 4, 2024 · PRINCETON, NJ, USA I SHANGHAI and SUZHOU, China I December 3, 2024 I Duality Biologics (“DualityBio”), a clinical-stage biotech company focusing on the discovery and development of next-generation antibody-drug conjugate (ADC) therapeutics, today announced that it has entered into an exclusive option agreement with GSK for a potentially best-in-class ADC candidate, DB-1324.
U.S. FDA Approves Pfizer’s HYMPAVZI™ (marstacimab-hncq) for …
Oct 12, 2024 · Custom Report. La Merie Publishing offers the service of preparing customized reports tailored to the needs and specifications of the customer. We conduct scientific & medical literature evaluations for clients of the biopharmaceutical industry within the scope of …